

Letter to the Editor

Dear Editor,



It is indeed a pleasure to see the continued expansion and progression of *Alzheimer's & Dementia: Diagnosis, Assessment and Disease Monitoring*, over the last 3 years. The editors and the editorial board are to be commended in the selection and publication of many important manuscripts that continue to advance the field's understanding of Alzheimer's and dementia, arguably perhaps one of the most important global public health problems.

As many readers appreciate, the Journal's title developed out of the early work by the Alzheimer's Association and the National Institute on Aging (NIA) to launch the International Alzheimer's Disease Research Portfolio (IADRP) project. The effort is credited with capturing the evolving nature of Alzheimer's disease research as funded by several different international sponsors. In addition, the project aimed to identify "opportunities for possible coordination of support for Alzheimer's disease research" and "funding gaps as well as areas of overlap within and across domestic and international funding agencies". To help aid this effort in identifying important gaps, the Journal has played an important supporting role.

The *Alzheimer's & Dementia* journal family, which also includes *Alzheimer's & Dementia* and *Alzheimer's & Dementia: Translational Research & Clinical Interventions*, is focused on several pressing challenges confronting the field. These include the inadequacy of current treatments to alleviate the symptoms of the disease. Also, the difficulty in developing novel interventions to detect [1–57], delay [58–69], or halt disease progression continues to be an important hurdle. The well-recognized public health and economic imperative [70–83] posed by the disease continues to be an important motivator to communicate new knowledge across multiple disciplines that will help increase the likelihood of unlocking the complexity of neurodegeneration [84–90] associated with many dementing illnesses.

The Editors within the journal family are challenging authors and reviewers to calibrate articles that better

assimilate *what is known* with *emerging evidence*. The goal is to promote discussions on new approaches about the biology of dementing illnesses. To this extent, the Journal has successfully encouraged authors to use a variety of techniques for data collection, modeling, and analysis.

Sincerely,

Editorial Office, *Alzheimer's & Dementia*

Ara S. Khachaturian*

Alzheimer's & Dementia: The Journal of the Alzheimer's Association

Alzheimer's & Dementia: Translational Research & Clinical Interventions

Alzheimer's & Dementia: Diagnosis, Assessment and Disease Monitoring

References

- [1] Mayeda ER, Glymour MM, Quesenberry CP, Johnson JK, Perez-Stable EJ, Whitmer RA. Survival after dementia diagnosis in five racial/ethnic groups. *Alzheimer's Dement* 2017;13:761–9.
- [2] Burggren AC, Mahmood Z, Harrison TM, Siddarth P, Miller KJ, Small GW, et al. Hippocampal thinning linked to longer TOMM40 poly-T variant lengths in the absence of the APOE ε4 variant. *Alzheimer's Dement* 2017;13:739–48.
- [3] Mirza SS, Ikram MA, Bos D, Mihaescu R, Hofman A, Tiemeier H. Mild cognitive impairment and risk of depression and anxiety: A population-based study. *Alzheimer's Dement* 2017;13:130–9.
- [4] Rasmussen KL, Tybjaerg-Hansen A, Nordestgaard BoG, Frikke-Schmidt R. Plasma apolipoprotein E levels and risk of dementia-A Mendelian randomization study of 106,562 individuals. *Alzheimer's Dement* 2017; <https://doi.org/10.1016/j.jalz.2017.05.006>. [Epub ahead of print].
- [5] Osler M, Christensen GT, Garde E, Mortensen EL, Christensen K. Cognitive ability in young adulthood and risk of dementia in a cohort of Danish men, brothers, and twins. *Alzheimer's Dement* 2017; <https://doi.org/10.1016/j.jalz.2017.04.003>. [Epub ahead of print].
- [6] Tolppanen A-M, Taipale H, Hartikainen S. Head or brain injuries and Alzheimer's disease: A nested case-control register study. *Alzheimer's Dement* 2017; <https://doi.org/10.1016/j.jalz.2017.04.010>. [Epub ahead of print].
- [7] Karageorgiou E, Vessel KA. Brain rhythm attractor breakdown in Alzheimer's disease: Functional and pathologic implications. *Alzheimer's Dement* 2017;13:1054–67.
- [8] Ovod V, Ramsey KN, Mawuenyega KG, Bollinger JG, Hicks T, Schneider T, et al. Amyloid β concentrations and stable isotope labeling kinetics of human plasma specific to central nervous system amyloidosis. *Alzheimer's Dement* 2017;13:841–9.
- [9] Capozzo R, Sassi C, Hammer MB, Arcuti S, Zecca C, Barulli MR, et al. Clinical and genetic analyses of familial and sporadic

*Corresponding author. Tel.: 301-309-6730; Fax: (844) 309-6730.

E-mail address: adj_xed@kra.net

URL: <http://www.alzheimersanddementia.org>, <http://adj.edmgr.com>

- frontotemporal dementia patients in Southern Italy. *Alzheimer's Dement* 2017;13:858–69.
- [10] Brenowitz WD, Hubbard RA, Keene CD, Hawes SE, Longstreth WT, Woltjer RL, et al. Mixed neuropathologies and estimated rates of clinical progression in a large autopsy sample. *Alzheimer's Dement* 2017; 13:654–62.
- [11] Lam B, Khan A, Keith J, Rogaeva E, Bilbao J, St. George-Hyslop P, et al. Characterizing familial corticobasal syndrome due to Alzheimer's disease pathology and PSEN1 mutations. *Alzheimer's Dement* 2017;13:520–30.
- [12] Leeuwis AE, Benedictus MR, Kuijter JPA, Binnewijzend MAA, Hooghiemstra AM, Verfaillie SCJ, et al. Lower cerebral blood flow is associated with impairment in multiple cognitive domains in Alzheimer's disease. *Alzheimer's Dement* 2017;13:531–40.
- [13] Jaraj D, Wikkello C, Rabiei K, Marlow T, Jensen C, Ostling S, et al. Mortality and risk of dementia in normal-pressure hydrocephalus: A population study. *Alzheimer's Dement* 2017;13:850–7.
- [14] Handels RLH, Vos SJB, Kramerberger MG, Jelic V, Blennow K, van Buchem M, et al. Predicting progression to dementia in persons with mild cognitive impairment using cerebrospinal fluid markers. *Alzheimer's Dement* 2017;13:903–12.
- [15] Toledo JB, Arnold M, Kastenmuller G, Chang R, Baillie RA, Han X, et al. Metabolic network failures in Alzheimer's disease: A biochemical road map. *Alzheimer's Dement* 2017;13:965–84.
- [16] Fardo DW, Gibbons LE, Mukherjee S, Glymour MM, McCormick W, McCurry SM, et al. Impact of home visit capacity on genetic association studies of late-onset Alzheimer's disease. *Alzheimer's Dement* 2017;13:933–9.
- [17] Farina N, Page TE, Daley S, Brown A, Bowling A, Basset T, et al. Factors associated with the quality of life of family carers of people with dementia: A systematic review. *Alzheimer's Dement* 2017;13:572–81.
- [18] Then FS, Luck T, Hesser K, Ernst A, Posselt T, Wiese B, et al. Which types of mental work demands may be associated with reduced risk of dementia? *Alzheimer's Dement* 2017;13:431–40.
- [19] Drachman DA, Smith TW, Alkamachi B, Kane K. Microvascular changes in Down syndrome with Alzheimer-type pathology: Insights into a potential vascular mechanism for Down syndrome and Alzheimer's disease. *Alzheimer's Dement* 2017; <https://doi.org/10.1016/j.jalz.2017.05.003>. [Epub ahead of print].
- [20] Burns JM, Johnson DK, Liebmann EP, Bothwell RJ, Morris JK, Vidoni ED. Safety of disclosing amyloid status in cognitively normal older adults. *Alzheimer's Dement* 2017;13:1024–30.
- [21] Knopman D, Alford E, Tate K, Long M, Khachaturian AS. Patients come from populations and populations contain patients. A two-stage scientific and ethics review: The next adaptation for single institutional review boards. *Alzheimer's Dement* 2017;13:940–6.
- [22] Willette AA, Webb JL, Lutz MW, Bendlin BB, Wennberg AM, Oh JM, et al. Family history and TOMM40 *523 interactive associations with memory in middle-aged and Alzheimer's disease cohorts. *Alzheimer's Dement* 2017;13:1217–25.
- [23] Yu L, Lutz MW, Farfel JM, Wilson RS, Burns DK, Saunders AM, et al. Neuropathologic features of TOMM40 *523 variant on late-life cognitive decline. *Alzheimer's Dement* 2017; <https://doi.org/10.1016/j.jalz.2017.05.002>. [Epub ahead of print].
- [24] Mukherjee S, Russell JC, Carr DT, Burgess JD, Allen M, Serie DJ, et al. Systems biology approach to late-onset Alzheimer's disease genome-wide association study identifies novel candidate genes validated using brain expression data and *Caenorhabditis elegans* experiments. *Alzheimer's Dement* 2017;13:1133–42.
- [25] Tagliafierro L, Glenn O-C, Zamora ME, Beach TG, Woltjer RL, Lutz MW, et al. Genetic analysis of α -synuclein 3' untranslated region and its corresponding microRNAs in relation to Parkinson's compared to dementia with Lewy bodies. *Alzheimer's Dement* 2017;13:1237–50.
- [26] Felsky D, Xu J, Chibnik LB, Schneider JA, Knight J, Kennedy JL, et al. Genetic epistasis regulates amyloid deposition in resilient aging. *Alzheimer's Dement* 2017;13:1107–16.
- [27] Verghese J, Lipton R, Ayers E. Spatial navigation and risk of cognitive impairment: A prospective cohort study. *Alzheimer's Dement* 2017; 13:985–92.
- [28] Illan-Gala I, Vilaplana E, Pegueroles J, Montal V, Alcolea D, Blesa R, et al. The pitfalls of biomarker-based classification schemes. *Alzheimer's Dement* 2017;13:1072–4.
- [29] Czaja S, Gold M, Bain LJ, Hendrix JA, Carrillo MC. Potential roles of digital technologies in clinical trials. *Alzheimer's Dement* 2017; 13:1075–6.
- [30] Roalf DR, Moore TM, Mechanic-Hamilton D, Wolk DA, Arnold SE, Weintraub DA, et al. Bridging cognitive screening tests in neurologic disorders: A crosswalk between the short Montreal Cognitive Assessment and Mini-Mental State Examination. *Alzheimer's Dement* 2017; 13:947–52.
- [31] Wolf D, Bocchetta M, Boccardi M, Bocchetta M, Preboske GM, Boccardi M, et al. Reference standard space hippocampus labels according to the European Alzheimer's Disease Consortium–Alzheimer's Disease Neuroimaging Initiative harmonized protocol: Utility in automated volumetry. *Alzheimer's Dement* 2017; 13:893–902.
- [32] Grill JD, Cox CG, Kremen S, Mendez MF, Teng E, Shapira J, Ringman JM, Apostolova LG. Patient and caregiver reactions to clinical amyloid imaging. *Alzheimer's Dement* 2017;13:924–32.
- [33] Wong MW, Braidy N, Poljak A, Pickford R, Thambisetty M, Sachdev PS. Dysregulation of lipids in Alzheimer's disease and their role as potential biomarkers. *Alzheimer's Dement* 2017;13:810–27.
- [34] Jia J, Gauthier S, Pallotta S, Ji Y, Wei W, Xiao S, et al. Consensus-based recommendations for the management of rapid cognitive decline due to Alzheimer's disease. *Alzheimer's Dement* 2017;13:592–7.
- [35] Mapstone M, Cheema AK, Zhong X, Fiandaca MS, Federoff HJ. Biomarker validation: Methods and matrix matter. *Alzheimer's Dement* 2017;13:592–7.
- [36] Thambisetty M, Casanova R, Varma S, Legido Quigley C. Peril beyond the winner's curse: A small sample size is the bane of biomarker discovery. *Alzheimer's Dement* 2017;13:606–7.
- [37] Ni R, Gillberg P-G, Bogdanovic N, Viitanen M, Myllykangas L, Nennesmo I, et al. Amyloid tracers binding sites in autosomal dominant and sporadic Alzheimer's disease. *Alzheimer's Dement* 2017; 13:419–30.
- [38] Wang R, Fratiglioni L, Kalpouzos G, Lovden M, Laukka EJ, Bronge L, et al. Mixed brain lesions mediate the association between cardiovascular risk burden and cognitive decline in old age: A population-based study. *Alzheimer's Dement* 2017;13:247–56.
- [39] Weintraub S, Randolph C, Bain L, Hendrix JA, Carrillo MC. Is cognitive decline measurable in preclinical Alzheimer's disease? *Alzheimer's Dement* 2017;13:322–3.
- [40] Rockwood K, Howlett SE, Hoffman D, Schindler R, Mitnitski A. Clinical meaningfulness of Alzheimer's Disease Assessment Scale-Cognitive subscale change in relation to goal attainment in patients on cholinesterase inhibitors. *Alzheimer's Dement* 2017; 13:1098–106.
- [41] Kaniyappan S, Chandupatla RR, Mandelkow E-M, Mandelkow E. Extracellular low-n oligomers of tau cause selective synaptotoxicity without affecting cell viability. *Alzheimer's Dement* 2017; 13:1270–91.
- [42] Kielb S, Rogalski E, Weintraub S, Rademaker A. Objective features of subjective cognitive decline in a United States national database. *Alzheimer's Dement* 2017; <https://doi.org/10.1016/j.jalz.2017.04.008>. [Epub ahead of print].
- [43] Hansson O, Palmqvist S, Ljung H, Cronberg T, van Westen D, Smith R. Cerebral hypoperfusion is not associated with an increase in amyloid β pathology in middle-aged or elderly people. *Alzheimer's Dement* 2017; <https://doi.org/10.1016/j.jalz.2017.06.2265>. [Epub ahead of print].
- [44] Sepulcre J, Sabuncu MR, Li Q, El Fakhri G, Sperling R, Johnson KA. Tau and amyloid- β proteins distinctively associate to functional

Download English Version:

<https://daneshyari.com/en/article/8680325>

Download Persian Version:

<https://daneshyari.com/article/8680325>

[Daneshyari.com](https://daneshyari.com)